CVS Health Corporation $CVS Shares Newly Purchased by USA Financial Formulas

Posted by Geri Gentry on Oct 18th, 2026

USA Financial Formulas bought a new position in CVS Health Corporation (NYSE:CVS – Free Report) in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 8,165 shares of the pharmacy operator’s stock, valued at approximately $700,000.

Several other large investors also recently made changes to their positions in the company. BlackRock Inc. bought a new stake in shares of CVS Health during the second quarter valued at approximately $12,747,462,000. State Street Corp grew its holdings in CVS Health by 26.3% in the 2nd quarter. State Street Corp now owns 74,927,064 shares of the pharmacy operator’s stock worth $7,751,205,000 after buying an additional 15,604,883 shares in the last quarter. Wellington Management Group LLP grew its holdings in CVS Health by 49.8% in the 2nd quarter. Wellington Management Group LLP now owns 33,801,113 shares of the pharmacy operator’s stock worth $3,496,725,000 after buying an additional 11,233,381 shares in the last quarter. Bank of America Corp DE grew its holdings in CVS Health by 148.0% in the 2nd quarter. Bank of America Corp DE now owns 23,188,670 shares of the pharmacy operator’s stock worth $2,398,868,000 after buying an additional 13,836,701 shares in the last quarter. Finally, Pzena Investment Management LLC acquired a new stake in CVS Health in the 2nd quarter valued at approximately $1,217,558,000. Institutional investors and hedge funds own 80.66% of the company’s stock.

CVS Health Price Performance

Shares of CVS Health stock opened at $92.41 on Friday. The company has a current ratio of 0.87, a quick ratio of 0.66 and a debt-to-equity ratio of 0.74. The company’s 50-day moving average price is $91.74 and its two-hundred day moving average price is $93.02. CVS Health Corporation has a 52 week low of $69.51 and a 52 week high of $110.68. The stock has a market cap of $118.19 billion, a PE ratio of 24.45, a price-to-earnings-growth ratio of 0.86 and a beta of 0.60.

CVS Health (NYSE:CVS – Get Free Report) last issued its quarterly earnings results on Wednesday, August 5th. The pharmacy operator reported $2.58 earnings per share for the quarter, beating analysts’ consensus estimates of $1.87 by $0.71. The company had revenue of $106.10 billion during the quarter, compared to the consensus estimate of $100.03 billion. CVS Health had a net margin of 1.18% and a return on equity of 13.12%. CVS Health’s revenue was up 7.3% on a year-over-year basis. During the same period in the prior year, the company earned $1.81 EPS. CVS Health has set its FY 2026 guidance at 7.900-8.100 EPS. As a group, sell-side analysts anticipate that CVS Health Corporation will post 8.02 EPS for the current fiscal year.

CVS Health Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Monday, November 2nd. Investors of record on Thursday, October 22nd will be paid a dividend of $0.6650 per share. The ex-dividend date of this dividend is Thursday, October 22nd. This represents a $2.66 annualized dividend and a yield of 2.9%. CVS Health’s dividend payout ratio is currently 70.37%.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on CVS shares. Royal Bank Of Canada increased their price target on CVS Health from $107.00 to $113.00 and gave the stock an “outperform” rating in a research note on Thursday, July 9th. Robert W. Baird set a $107.00 price target on CVS Health in a report on Thursday, August 6th. Wall Street Zen upgraded shares of CVS Health from a “buy” rating to a “strong-buy” rating in a research note on Sunday, October 11th. HSBC reaffirmed a “hold” rating and issued a $103.00 price objective on shares of CVS Health in a report on Monday, July 6th. Finally, Truist Financial increased their target price on shares of CVS Health from $108.00 to $118.00 and gave the company a “buy” rating in a research report on Tuesday, July 14th. Twenty analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $107.80.

View Our Latest Research Report on CVS Health

CVS Health News Summary

Here are the key news stories impacting CVS Health this week:

Positive Sentiment: Value and dividend appeal: Zacks identifies CVS as a potentially attractive long-term value stock, while a separate dividend roundup highlights CVS among income-oriented companies. These reports may support investor interest, although they do not represent new company guidance. Why CVS Health Is a Top Value Stock for the Long-Term Dividend roundup
Positive Sentiment: Care-management and consumer initiatives: CVS Caremark is promoting more connected, personalized pharmacy-benefit experiences. CVS also announced a women’s midlife-health research collaboration and highlighted Signify Health’s at-home heart-rhythm monitoring for eligible members. These efforts could strengthen engagement and differentiate CVS’s health-services platform, but the articles provide no immediate financial targets. CVS Caremark Is Transforming the Health Care Experience CVS Health midlife-health collaboration
Neutral Sentiment: CVS Caremark appeared in a consumer-focused segment explaining pharmacy benefits as customers evaluate insurance plans. The exposure may improve public understanding of the business but is unlikely to materially affect near-term earnings. CVS Caremark explains pharmacy benefits
Negative Sentiment: Medicare Advantage exposure: Reports that Medicare Advantage plans, including a CVS plan, will leave New Hampshire raise concerns about membership losses and pressure on the company’s government-business outlook. The specific financial impact was not disclosed. Medical Advantage plans leaving New Hampshire
Negative Sentiment: Legal overhang: CVS faces a reported $315 million settlement related to allegations involving dangerous opioid prescriptions. Even if the payment is manageable relative to CVS’s size, the matter adds costs and reputational risk. CVS opioid settlement

About CVS Health

(Free Report)

CVS Health Corporation (NYSE: CVS) is a diversified health care company that provides pharmacy, insurance and health services in the United States. Its businesses serve consumers, employers, health plans and health care providers through pharmacies, benefit programs, insurance coverage and clinical care services.

The company’s Pharmacy Services segment, led by CVS Caremark, manages prescription drug benefits for employers, insurers and government programs. CVS Pharmacy operates retail pharmacies and health-focused stores that dispense prescriptions and offer over-the-counter products, health and wellness merchandise, immunizations and related services.